REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
18/02/2025
Voltar para busca
Dado oficial do USPTO
OXC-BETA
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: Estados Unidos
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
48
Atualização mais recente
18/02/2025
Tipo de marca
Verbal
Classes Nice
5
Data de depósito
11/07/2016
Data de registro
18/02/2020
Data de expiração
-
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
18/02/2020
Última transação
18/02/2025
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use, Foreign priority
Código do desenho
4
Tipo de titular
03
Localização do titular
Ottawa, Ontario, CA
Examinador
RINKER, ANTHONY
Unidade examinadora
L20
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
Avivagen Inc.
Representantes
Jeffrey J. Ellison Clark+Elbing LLP
Classificação técnica
Classes Nice
Classe 5
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Adjuvants for use with vaccines; Animal feed additives and supplements; Anti-infective products for veterinary use; Anti-inflammatories; Dietarynutritionals and food supplements; Nutritional supplements for general health and well-being; Dietary food supplements for general health and well-being; Medicated dermatological preparations and substances; Medicated skin care preparations; Non-medicated additives for animal feed for use as nutritional supplements; Nutritional supplements for supporting immune function; Nutritional supplements for catsdogshorseslivestock; Pharmaceutical preparations for treatment of infectious diseasesrespiratory infectionseye infections; Pharmaceutical preparations for animal skincare; Pharmaceutical preparations for treating skin disorders; Pharmaceutical preparations for use in dermatology; Pharmaceutical preparations and substances for the treatment of viralrespiratorygastrointestinaldermatologicalimmune system related diseases and disorders; Pharmaceutical preparations for the prevention and treatment of bacteria-based diseases or disorders; Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Pharmaceutical preparations for skin care; Pharmaceutical preparations for the treatment of bacterial infections; Pharmaceutical preparations for the treatment of bacterial skin infectionsfungal skin infectionsviral skin infections and parasitic skin infections; Pharmaceutical preparations for the prevention and treatment of disorders of the immune systemPharmaceutical preparations for treatment of respiratory diseasesdisorders and infections; Pharmaceutical preparations for the treatment of inflammatory disorders and diseasesinflammatory bowel diseasesinflammatory connective tissue diseases; Pharmaceutical preparations for use in dermatology; Pharmaceutical preparations for use in gastroenterology; Pharmaceutical products for skin care for animals; Pharmaceutical products for the treatment of joint disease; Pharmaceutical products for treating respiratory diseases; Veterinary preparations for treatment of intestinal bacteria; Veterinary pharmaceutical preparations for animals and poultry to give newborn animals and birds a healthy start; Veterinary pharmaceutical preparations for respiratory and reproductive diseases in cattle; Veterinary pharmaceutical preparations for treatment of bacterial infections in dogs; Veterinary pharmaceutical preparations for the treatment of infectious diseases in poultry; Veterinary pharmaceutical preparations for treatment of infectious diseaserespiratory infectionseye infectionstopical infections; Veterinary pharmaceutical preparations for the treatment of infectious diseasesswine dysenterybacterial enteritisbluecombpneumonia; Veterinary pharmaceutical preparations for the treatment of swine bacterial infectious diseases; Veterinary pharmaceutical preparations for treatment of intestinal bacteria
Publicações
Histórico de despachos e eventos da marca no USPTO.
48 publicações encontradas
R.PR
REGISTERED-PRINCIPAL REGISTER
18/02/2020
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
03/12/2019
PUBO
PUBLISHED FOR OPPOSITION
03/12/2019
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
13/11/2019
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
28/10/2019
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
24/10/2019
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
23/10/2019
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
23/10/2019
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
22/10/2019
GNS2
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
11/10/2019
GNSI
INQUIRY TO SUSPENSION E-MAILED
11/10/2019
CNSI
SUSPENSION INQUIRY WRITTEN
11/10/2019
RCCK
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
23/09/2019
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
18/03/2019
GNSL
LETTER OF SUSPENSION E-MAILED
18/03/2019
CNSL
SUSPENSION LETTER WRITTEN
18/03/2019
RCCK
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
26/02/2019
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
16/08/2018
GNSL
LETTER OF SUSPENSION E-MAILED
16/08/2018
CNSL
SUSPENSION LETTER WRITTEN
16/08/2018
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
01/08/2018
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
01/08/2018
ALIE
ASSIGNED TO LIE
31/07/2018
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
27/07/2018
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
19/07/2018
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
19/07/2018
GNS2
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
23/05/2018
GNSI
INQUIRY TO SUSPENSION E-MAILED
23/05/2018
CNSI
SUSPENSION INQUIRY WRITTEN
23/05/2018
RCCK
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
02/05/2018
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
18/10/2017
GNSL
LETTER OF SUSPENSION E-MAILED
18/10/2017
CNSL
SUSPENSION LETTER WRITTEN
18/10/2017
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
27/09/2017
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
27/09/2017
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
26/09/2017
GNS2
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
22/05/2017
GNSI
INQUIRY TO SUSPENSION E-MAILED
22/05/2017
CNSI
SUSPENSION INQUIRY WRITTEN
22/05/2017
RCCK
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
09/05/2017
ALIE
ASSIGNED TO LIE
05/05/2017
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
27/10/2016
GNSL
LETTER OF SUSPENSION E-MAILED
27/10/2016
CNSL
SUSPENSION LETTER WRITTEN
27/10/2016
DOCK
ASSIGNED TO EXAMINER
19/10/2016
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
15/07/2016
NWAP
NEW APPLICATION ENTERED
14/07/2016
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace OXC-BETA ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.